Galecto

Galecto Announces Acquisition of Damora Therapeutics Galecto Acquires Damora Therapeutics, Pays ~$284.9M In Form Of Private Placement Of Series C Non-Voting Convertible Preferred Stock /Galecto, Inc. （”Galecto”） today announced the completion of the acquisition of Damora Therapeutics, Inc. （”Damora”）， a... Read more